We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.02B
AUM Growth
+$67.6M
Cap. Flow
+$92.8M
Cap. Flow %
9.11%
Top 10 Hldgs %
47.33%
Holding
173
New
45
Increased
25
Reduced
30
Closed
56

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$31.8M
2
FOLD
Amicus Therapeutics
FOLD
+$26.7M
3
ZBH icon
Zimmer Biomet
ZBH
+$24.4M
4
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$22.7M
5
INSM icon
Insmed
INSM
+$21.6M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$17.8M
2
TSRO
TESARO, Inc.
TSRO
+$15.8M
3
EXAS
Exact Sciences
EXAS
+$12.7M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 82.29%
2 Miscellaneous 14.83%
3 Consumer Staples 1.81%
4 Financials 1.05%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
101
Humana
HUM
$47.6B
$103K 0.01%
803
-447
-36% -$52.9K
MGLN
102
DELISTED
Magellan Health Services, Inc.
MGLN
$102K 0.01%
+1,642
New +$96.5K
MDAS
103
DELISTED
MEDASSETS INC COM STK (DE)
MDAS
$101K 0.01%
+4,429
New +$104K
CRL icon
104
Charles River Laboratories
CRL
$13B
$100K 0.01%
+1,860
New +$102K
IQV icon
105
IQVIA
IQV
$44.4B
$100K 0.01%
+1,875
New +$94.6K
BSTC
106
DELISTED
BioSpecifics Technologies Corp.
BSTC
$100K 0.01%
+3,700
New +$96.4K
MCK icon
107
McKesson
MCK
$105B
$99K 0.01%
+530
New +$94.3K
SMA
108
DELISTED
SYMMETRY MEDICAL INC
SMA
$99K 0.01%
+11,148
New +$97.2K
MRGE
109
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
$99K 0.01%
+43,478
New +$98.9K
PDLI
110
DELISTED
PDL BioPharma, Inc.
PDLI
$99K 0.01%
+10,183
New +$90.8K
PMC
111
DELISTED
PharMerica Corporation
PMC
$98K 0.01%
+3,441
New +$95.7K
WCG
112
DELISTED
Wellcare Health Plans, Inc.
WCG
$97K 0.01%
+1,302
New +$92.9K
BCR
113
DELISTED
CR Bard Inc.
BCR
$97K 0.01%
+676
New +$96.6K
AMSG
114
DELISTED
Amsurg Corp
AMSG
$90K 0.01%
+1,980
New +$90.9K
ABBV icon
115
AbbVie
ABBV
$465B
– –
-67,000
Closed -$3.44M
ABUS icon
116
PUT
Arbutus Biopharma
ABUS
$1B
– –
-100,000
Closed -$2.15M
AGEN
117
Agenus
AGEN
$322M
– –
-10,190
Closed -$634K
ALNY icon
118
Alnylam Pharmaceuticals
ALNY
$31.9B
– –
-50,000
Closed -$3.36M
ANIP icon
119
ANI Pharmaceuticals
ANIP
$1.66B
– –
-45,000
Closed -$1.41M
ATRC icon
120
AtriCure
ATRC
$2.86B
– –
-100,000
Closed -$1.88M
BLUE
121
DELISTED
bluebird bio
BLUE
– –
-1,544
Closed -$455K
CGEN icon
122
Compugen
CGEN
$228M
– –
-170,000
Closed -$1.79M
CI icon
123
Cigna
CI
$76.3B
– –
-1,269
Closed -$106K
CYTK icon
124
CALL
Cytokinetics
CYTK
$9.64B
– –
-700,000
Closed -$6.65M
DVA icon
125
DaVita
DVA
$12.2B
– –
-2,382
Closed -$164K
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2014 Portfolio in Review

As of Q2 2014, Perceptive Advisors held 173 positions worth $1.02B, up 7.1% from $952M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $92.8M of net new capital in Q2 2014, opening 45 new positions and adding to 25 existing holdings. Its largest new stake was Zimmer Biomet: 249,775 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $17.8M trimmed.

  • Perceptive Advisors's largest Q2 2014 buy was Zimmer Biomet: 249,775 shares worth $25.2M.
  • Perceptive Advisors added most to QUESTCOR PHARMA INC in Q2 2014, an estimated $31.8M increase.
  • Perceptive Advisors's biggest Q2 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $17.8M.
  • Perceptive Advisors fully exited Endocyte, Inc. Common Stock in Q2 2014, selling an estimated $10.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.02B portfolio in Q2 2014.
  • Perceptive Advisors opened 45 new positions and closed 56 in Q2 2014.
  • Perceptive Advisors's portfolio value rose 7.1% quarter-over-quarter to $1.02B.

Based on Perceptive Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.